Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Leukemia • Lymphoma • Internal Medicine • CLL • Hematology
Would it be reasonable to offer a patient with CLL a treatment break from acalabrutinib or any BTK inihibitor after a period of time, assuming good response?
It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about real world experience here, where financial toxicity and "acceptable toxicity" are real things patients still suffer from.
Answer from: Medical Oncologist at Academic Institution
It is certainly reasonable to take breaks and I have done this for certain patients in my practice. For example, in older or frail patients whose disease is already under great control, I think it is reasonable to have a “drug holiday”. With continuous long-term use, it is almost inevita...
Sign in or Register to read more